Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study |
| |
| Authors: | Masaki Inoue MD Yoshiaki Tanaka Nagatoshi Sugita Masato Yamasaki Tadashi Yamanaka Junnosuke Minagawa Karo Nakamuro Toshiro Tani Yoshio Okudaira Tuguhiro Karita Katsumi Takayama Tatsuo Ide Osamu Tanizawa |
| |
| Institution: | (1) Department of Obstetrics and Gynecology, Osaka University Medical School, 1-1-50, Fukushima, Fukushima-ku, 553 Osaka, Japan;(2) Department of Obstetrics and Gynecology, Suita City Hospital, Japan;(3) Department of Obstetrics and Gynecology, Sakai City Hospital, Japan;(4) Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Japan;(5) Department of Obstetrics and Gynecology, Itami City Hospital, Japan;(6) Department of Obstetrics and Gynecology, Minoh City Hospital, Japan;(7) Department of Obstetrics and Gynecology, Osaka Furitsu Hospital, Japan;(8) Department of Obstetrics and Gynecology, Kaisei Hospital, Japan;(9) Department of Obstetrics and Gynecology, Biken Hospital, Japan;(10) Department of Obstetrics and Gynecology, Toyonaka City Hospital, Japan;(11) Department of Obstetrics and Gynecology, Keisatsu Hospital, Japan;(12) Department of Obstetrics and Gynecology, Kaizuka City Hospital, Japan |
| |
| Abstract: | The effect of immunotherapy using sizofiran (SPG) on the prognosis of patients with ovarian cancers was prospectively studied in a total of 68 patients, who were randomly assigned to either a cisplatin, adriamycin and cyclophosphamide (PAC) therapy group or a PAC plus SPG combination therapy group.The survival rate was significantly higher in patients with stage Ic, II or III cancers treated with the PAC plus SPG combination, compared with the patients treated with PAC alone. In the SPG-receiving patients with stage Ic or more advanced cancers who were treated with four cycles or more of PAC, the outcome was improved (Cox-Mantel, p=0.074; generalized Kruskal-Wallis, p=0.032). Similar improvement was also observed in the patients with non-serous adenocarcinomas (Cox-Mantel, p-0.076; generalized Krukal-Wallis, p=0.045). No side effects attributable to SPG were recorded.The present results suggest that the use of SPG in combination with long-term chemotherapy improves the postoperative prognosis in ovarian cancer patients.Abbreviations SPG
sizofiran |
| |
| Keywords: | Immunotherapy Ovarian Cancer Prognosis Sizofiran |
| 本文献已被 SpringerLink 等数据库收录！ |
|
